New biologic therapies in patients with Inflammatory Bowel Disease [Nuovi farmaci biologici nelle Malattie Infiammatorie Croniche Intestinali]

The proven involvement of cytokines in the pathophysiology of Inflammatory Bowel Disease (IBD) has led to the development of powerful, selective, anticytokine drugs, so called biologics. Biologic therapies for IBD like Infliximab have revolutionized the treatment of patients with Crohn's disease and have begun to have an impact on therapy for refractory ulcerative colitis.